TEL AVIV, Israel , Nov. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate overview via a Fireside Chat...

TEL AVIV, Israel , Nov. 17, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced the pricing of its previously announced underwritten...

TEL AVIV, Israel , Nov. 16, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it is offering to sell 2,500,000 ordinary shares in...

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Nov. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced...

TEL AVIV, Israel , Nov. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Andrew Brenner , MD, will present a poster on VB-111...

TEL AVIV, Israel , Nov. 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast...

 Agreement includes $15 million up front, potential milestones payments of more than $100 million, as well as tiered high-teen royalties NanoCarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world TEL AVIV, Israel, Nov....

TEL AVIV, Israel , Oct. 23, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today the opening of its new gene therapy manufacturing plant in Modiin, Israel . This plant will be the commercial facility for production of the Company’s lead product candidate, ofranergene obadenovec...

New EMA orphan approval for Ovarian Cancer complements previously granted VB-111 orphan status for Glioblastoma in the US and Europe TEL AVIV, Israel , Oct. 20, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and...

Top-line data expected in Q1 2018 TEL AVIV, Israel , Oct. 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the independent Data Safety Monitoring Committee (DSMC) met on September 28, 2017 to conduct its third and final safety review of the Phase 3 GLOBE Study...